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Abstract 
Background: Stargardt disease (STGD) and age-related macular degeneration (AMD) share clinical and pathophysi-
ological features. In AMD, macular hyperpigmentary changes are associated to a worse prognosis. The purpose of 
this study was to characterize macular hyperpigmentary changes in patients with STGD and associate them with the 
severity of phenotype.
Materials and methods: This retrospective cross-sectional study included 141 patients with STGD. Hyperpigmentary 
changes were evaluated on color fundus photography and spectral-domain optical coherence tomography. Severity 
of phenotype was assessed by full-field electroretinogram (ffERG) and fundus autofluorescence (FAF) patterns, and 
visual acuity (VA).
Results: Thirty patients (21.7%) showed macular hyperpigmentary changes in four distinct patterns. Out of seven-
teen patients who had follow-up images, eleven patients demonstrated increases of the hyperpigmented lesions, 
and progression of the underlying RPE atrophy overtime. VA remained stable. Of 28 patients who had ffERG, 17 
patients presented with reduction of photopic and scotopic responses, while 8 presented with reduction of photopic 
responses only, and 3 presented with preserved photopic and scotopic responses. Of 25 patients who had FAF avail-
able, 12 presented with widespread disease extending anteriorly to the vascular arcades, while eight presented with 
widespread disease, extending beyond the vascular arcades, and 5 presented with disease confined to the foveal area.
Conclusion: In this study, we demonstrated that patients with STGD with macular hyperpigmented lesions had a 
severe phenotype. Overtime, hyperpigmented lesions increased in size, spread across the retina, and migrated to dif-
ferent retinal layers. Macular hyperpigmentation may be a marker of advanced stage of the disease.
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Introduction
Macular atrophy is a manifestation of Stargardt disease 
(STGD) and of age-related macular degeneration (AMD) 
[1]. STGD is the most common inherited macular dys-
trophy in both children and adults, caused by pathogenic 
variants in the ABCA4 gene [2]; whereas AMD is a mul-
tifactorial disease and the leading cause of blindness in 
the elderly [3]. Many factors are known to be associated 
with the physiopathology underlying the development 
of retinal pigment epithelium (RPE) atrophy in patients 
with STGD and AMD, and there is evidence that the 
toxic accumulation of lipofuscin and its bis-retinoid com-
ponents, including N-retinylidene-N-retinylethanola-
mine (A2E), play a role in both conditions [4–6]. The A2E 
accumulates in the RPE and photoreceptors, leading to 
the degeneration of these cells [4, 5, 7].
Clinically, STGD and AMD also share common fea-
tures, such as decreased central vision, bilaterality, and 
macular atrophy. In STGD, the macular atrophy is usu-
ally symmetric and may be accompanied by flecks [8, 9]. 
Two prognostic factors have been associated with disease 
progression: fundus autofluorescence (FAF) and full-field 
electroretinogram (ffERG) patterns at baseline [10, 11]. 
Patients with multiple and widespread lesions on FAF 
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and with cone-rod dysfunction on ffERG tend to exhibit 
a more severe phenotype than do those with localized 
macular changes and normal function of rods and cones 
[10, 11]. In AMD, on the other hand, patients most com-
monly present with drusen and pigmentary changes and 
develop macular atrophy (dry AMD) and/or choroidal 
neovascularization (wet AMD) over time [12]. In AMD, 
three major factors have been associated to the disease 
progression: the presence of large drusen [13], large 
drusen areas, and pigmentary changes [12, 14–17].
In AMD, pigmentary changes either consist of hypo-
pigmentation represented by depigmented areas not 
related to geographic atrophy or by hyperpigmenta-
tion represented by deposits of gray-black pigment on 
the fundus exam [12, 18]. The hyperpigmentation is 
thought to result from RPE degeneration, displacement, 
or migration [19–21]. Clinical studies have corroborated 
this theory by demonstrating a correlation between pig-
ment clumping observed on color fundus photography 
(CFP) with hyperreflective foci in several retinal layers, 
including the outer nuclear layer (ONL), outer plexiform 
layer (OPL), and inner nuclear layer (INL) on spectral 
domain optical coherence tomography (SD-OCT) [22, 
23]. Although the association of hyperpigmentation with 
disease etiology in AMD has already been described, to 
our knowledge, the presence and significance of hyper-
pigmented changes and associated RPE changes in 
patients with STGD are still poorly defined. The aim of 
this study was to better characterize macular hyperpig-
mentary changes in patients with STGD and investigate 
the association of this finding with the severity of the 
clinical phenotype. We also provide some preliminary 
follow up data, which includes a comparison of the visual 
acuity at baseline and follow up, and the progression of 
both the number and density of macular hyperpigmen-
tary changes on color fundus photography and migration 
from outer to inner retinal layers on SD-OCT.
Materials and methods
A retrospective chart review was performed at the Kel-
logg Eye Center, at Michigan Medicine. The study was 
approved by the University of Michigan Institutional 
Review Board and conducted accordingly to the Declara-
tion of Helsinki.
Patient selection
We only included patients with both a clinical and 
genetic diagnosis of STGD. The clinical diagnosis was 
established by the presence of central vision dysfunc-
tion and bilateral macular atrophy, with or without sur-
rounding flecks on fundus exam. Genetic diagnosis was 
established by the presence of two or more pathogenic 
variants in the ABCA4 gene, where pathogenicity was 
determined by the genetic testing laboratory utilized for 
the given patient. In patients for whom segregation anal-
ysis was performed, variants were shown to be in trans. 
Patients with only one variant in ABCA4 were excluded.
Data collection
A review of electronic medical records was performed, 
and clinical data from baseline and from the most 
recent visit were collected for each patient. Clinical data 
included sex; estimated age of onset, based on when 
patients noticed first symptoms or when they were diag-
nosed; estimated disease duration, determined by the 
time between age of onset and the date when baseline 
images were acquired; visual acuity (VA) on the Snel-
len chart; ffERG responses; color fundus photography 
(CFP) imaging; fundus autofluorescence (FAF) imag-
ing; and spectral domain optic coherence tomography 
(SD-OCT) imaging. The ffERG was performed accord-
ing to the standards of the International Society for 
Clinical Electrophysiology of Vision (ISCEV). The ffERG 
results were divided into three groups, according to the 
classification system described by Mc Bain et  al. [10]: 
group 1 consisted of patients with normal photopic and 
scotopic responses; group 2 consisted of subjects with 
reduced photopic responses only; and group 3 con-
sisted of patients with reduced photopic and scotopic 
responses [10]. FAF was graded as one of three different 
types according to the classification system described 
by Fujinami et al. [11]: type 1 consisted of localized low 
signal at the fovea surrounded by a homogeneous back-
ground of autofluorescence; type 2 consisted of localized 
low signal at the macula surrounded by widespread foci 
of high and low signals extending anteriorly to the vascu-
lar arcades; and type 3 consisted of multiple areas of low 
signal throughout the posterior pole, extending beyond 
the vascular arcades. CFP images were analyzed for the 
presence of any sign of RPE clumping, defined as dark-
black colored lesions within the posterior pole. SD-OCT 
images were analyzed for the presence of hyperreflective 
foci. The correlation of hyperpigmentary changes seen on 
CFP and the infra-red image from SD-OCT was overlaid 
with the SD-OCT image, using methodology similar to 
that described in a previous study [23]. Only hyperpig-
mented lesions with a corresponding SD-OCT B-scan 
were included. All data were obtained from the baseline 
visit. When available, data from the most recent follow 
up visits were also collected.
Statistical analysis
Data were summarized into means and standard devia-
tions for continuous variables and with counts and per-
centages for categorical variables. Student t test was used 
to compare visual acuity data at baseline and follow-up 
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visits for those with macular hyperpigmentation only. 
Statistical analyses performed using SPSS, Version Pro 
12. SAS Institute Inc., Cary, NC, 1989-2007.
Results
Patients characteristics
Of 141 patients with both a clinical and genetic diagno-
sis of STGD, 30 patients (21.27%) had macular hyperpig-
mentation observed on CFP. There were 15 men and 15 
women, the mean age was 43.5 (standard deviation 16.4), 
the mean age of onset was 23 years (standard deviation 
2.52), and the mean duration of disease was 19.9  years 
(standard deviation 15.1). Macular hyperpigmentation 
was observed in both eyes in 25 patients (83.3%). Base-
line ffERG was available for 28 patients. The majority 
[17] of patients (60.7%) presented with reduction of pho-
topic and scotopic responses (ffERG group 3), while 8 
(28.5%) presented with reduction of photopic responses 
only (ffERG group 2), and 3 (5.1%) presented with pre-
served photopic and scotopic responses (ffERG group 
1). FAF at baseline was available for 25 patients. Twelve 
patients (48%) presented with type 2, while eight (32%) 
presented with type 3, and 5 (20%) presented with type 1 
autofluorescence.
Characteristics of hyperpigmentary changes
Hyperpigmentation was observed in four distinct pat-
terns in 55 eyes: pattern 1 consisted of focal areas of 
hyperpigmentation within well-demarcated areas of 
geographic atrophy; pattern 2 consisted of widespread 
RPE clumping within poorly demarcated atrophic areas; 
pattern 3 consisted of diffuse hyperpigmentation associ-
ated with subretinal fibrosis; and pattern 4 consisted of 
hyperpigmentation along retinal vasculature (perivenous 
pigmentation). In 35 eyes (63.6%), hyperpigmentation 
was associated with pattern 1, while in 18 eyes (51.4%) 
it was associated with pattern 2. Pattern 3 was observed 
in only 2 (3.6%) eyes. Perivenous hyperpigmentation was 
observed concomitantly in 10 eyes of patients with pat-
tern 2. Representative images of the four patterns are 
shown in Fig. 1.
SD-OCT was available for 22 patients (41 eyes). Eight 
patients and one eye were excluded from the SD-OCT 
analysis because the SD-OCT B-scans did not pass 
through the hyperpigmented lesions or because the 
Fig. 1 a Color photography of a patient with geographic atrophy and macular hyperpigmentation that is confined within areas of geographic 
atrophy (pattern 1). b Color photography of a patient with a diffuse hyperpigmentation in poorly-defined areas of atrophy (pattern 2). c Color 
photography of a patient with macular hyperpigmentation associated with subretinal fibrosis (pattern 3). d Color photography of a patient with 
perivenous pigment clumping throughout the macula (pattern 4) that also extends into the mid-periphery
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hyperpigmented lesions seen on CFP were not clearly 
identified on infra-red image on SD-OCT. Hyperpig-
mentation appeared as hyperreflective and highly back-
scattering lesions. In 31 eyes, hyperpigmentation was 
observed in the outer retina (comprising the IS/OS and 
RPE), while in 8 eyes, it was observed in the INL, ONL, 
ganglion cell layer (GCL) or retinal nerve fiber layer 
(RFNL) in addition to the IS/OS and RPE. Subretinal 
hyperpigmentation was observed in 2 eyes. SD-OCT 
images are shown in Fig. 2.
Progression
Seventeen (56.6%) patients had CFP follow-up images. 
Eleven patients (64.7%) demonstrated increases (for both 
distribution and density) of the hyperpigmented lesions, 
along with progression of the underlying RPE atro-
phy, between the baseline visit and the most recent visit 
(mean follow up of 6.58  years). In 8 eyes, the pigment 
observed in the outer retina expanded to the inner lay-
ers, including the INL, ONL, GCL or RNFL on SD-OCT. 
VA remained stable. There was no statistically significant 
difference between the mean VA at the baseline (0.935 
logMar) and the mean VA at the most recent visit (1.29 
logMar) (p = 0.21).
Discussion
In this study, it has been demonstrated that patients with 
STGD with hyperpigmented lesions in the posterior pole 
had a long disease duration and severe phenotype. This 
was confirmed by a poor VA, widespread disease on FAF, 
and photopic and scotopic dysfunction on ERG in those 
with MH. In addition, over time, hyperpigmented lesions 
increased in size, spread across the retina, and migrated 
to different retinal layers, as seen by SD-OCT. Macular 
hyperpigmentation may be a marker of advanced stage of 
the disease, when diffuse RPE atrophy leads to pathologic 
remodeling and clumping of the remaining RPE cells. 
Similarly, the development of peripheral pigmentation in 
patients with STGD has been previously associated with 
a severe phenotype and advanced disease stage. Previous 
Fig. 2 a SD-OCT shows hyperpigmented lesion localized in the outer retina. b SD-OCT shows hyperpigmented lesions located in the outer retina 
and pilling up towards the inner retina. c SD-OCT shows hyperpigmented lesion mostly located in the inner retina
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studies have demonstrated the presence of peripheral 
pigmented retinal lesions resembling CHRPE lesions in 
a subset of patients with STGD disease who also had a 
more severe phenotype [24]. Therefore hyperpigmen-
tation, whether in the macula or periphery, may be a 
marker of end-stage pathologic remodeling of the retina 
after many years of degeneration.
In patients with STGD, hyperpigmentation has been 
described following human embryonic stem cell-derived 
RPE (hESC-RPE) transplantation. In most eyes, hyper-
pigmentation was observed as subretinal hyperreflective 
foci at the border of atrophic areas, consistent with loca-
tion of hyperpigmentation in the RPE-transplanted cells 
[25, 26]. In a few eyes that underwent hESC-RPE trans-
plantation, a patch of epiretinal pigmentation also devel-
oped, which likely resulted from a reflux of the implanted 
material from the subretinal space or from injection into 
the pre-retinal space [25, 26]. In retinal dystrophies over-
all, RPE proliferation seems to occur in response to loss 
of surrounding RPE cells, which in turn leads to further 
retinal cell damage and loss [27, 28]. In our study, hyper-
pigmented lesions increased in size, spread across the 
retina, and migrated to different retinal layers over time. 
Therefore, it is possible that, similar to the pathogenesis 
of hyperpigmentation in patients with AMD and other 
retinal dystrophies, the hyperpigmentation observed in 
patients with STGD may also occur in response to loss of 
surrounding RPE cells, which in turn leads to further RPE 
damage and loss [27, 28], resulting in RPE degeneration, 
displacement and migration [19–21].
In AMD, macular hyperpigmentation occurs after 
extensive loss of the RPE and increases the risk of 
progression to either geographic atrophy or choroi-
dal neovascularization [22]. Comparisons have been 
made between patients with AMD and STGD in part 
due to the similar pathogenesis that characterizes these 
degenerative diseases [4–6]. Interestingly, the pres-
ence of a single heterozygous mutation in ABCA4 has 
been associated with an increased risk for AMD [29]. 
Considering that the use of RPE stem cell therapies are 
being investigated for both of these diseases, and that 
pathologic RPE remodeling is an important disease 
mechanism in both diseases, a robust understanding 
of RPE remodeling is necessary to anticipate possible 
outcomes for patients with STGD who undergo a thera-
peutic intervention. In STGD, macular hyperpigmen-
tation may not be predictive or causative of a severe 
phenotype, but it may be a finding associated with an 
advanced stage of disease, after extensive photore-
ceptor degeneration and RPE atrophy have occurred. 
The relationship between RPE atrophy, photorecep-
tor degeneration, and RPE remodeling in both of these 
macular diseases may elucidate more about the etiology 
of macular hyperpigmentation and lead to potential 
treatments that might reverse the pathologic remod-
eling seen in these degenerative retinal diseases.
The limitations of this study include its retrospective 
design and limited number of visual functional tests. 
The absence of change in VA between baseline and fol-
low up visits may have occurred because patients with 
STGD are known to have oscillation of the preferred 
retinal locus and have also been shown to reach a rela-
tive plateau in visual acuity at 20/200 [30–33]. In addi-
tion, in many cases, the areas of hyperpigmentation 
were outside the fovea, and, therefore, the effect of the 
lesions on visual function could not be evaluated only 
by measuring the central VA. The areas of geographic 
atrophy were also subjectively quantified, and, there-
fore, the association between progression of geographic 
atrophy and development of hyperpigmentary changes 
cannot be established.
Since cell and gene therapies are being developed 
for inherited retinal dystrophies, we need to be able to 
stratify patients by severity and progression of disease in 
order to optimize the ability to elicit successful responses 
to therapy. Clinical trials evaluating efficacy of novel 
therapies for patients with STGD may wish to document 
the presence of hyperpigmentation at baseline as well 
as after therapy. Furthermore, studies assessing other 
functional testing, such as microperimetry and contrast 
sensitivity, may provide insight into how these hyperpig-
mentary changes are associated with other visual func-
tion measures.
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